Cardiff Oncology, Inc.

NASDAQ:CRDF

Biotechnology

Healthcare
$0.84 +2.12%

+$0.03 today

Market cap
$65.27M
Beta
1.38
P/E (TTM)
-1.8
EPS (TTM)
-$0.65
52W Low $1.16High $4.56

Volume 0.86M

Average 1.05M

CRDF Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Cardiff Oncology, Inc.NASDAQ: CRDF

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 68.35M shares rose 43.4% year over year, in line with the +43.6% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 2.3% from the prior quarter. Over 3 fiscal years it compounded at +15.3% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +43.4% toward the trailing-twelve-month pace of +43.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
68.35M+2.3% QoQ
Last fiscal yearDec 2025
66.84M+40.3% YoY
LTMMar 2026
67.15M+43.6% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+43.4%——
1 year+40.3%——
3-year CAGR+15.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
66.84M USD
Year-over-year change
+40.3%
4-year CAGR
+14.4%

Weighted Avg Shares (Diluted) vs competitors

How CRDF compares with its peers on the latest reported figures

  • CRDF's LTM Mar 2026 weighted avg shares (diluted) of 67.15M shares is the 5th highest of the 9 companies compared; the peer median is 62.11M shares.
  • Its year-over-year change of +43.6% is the 3rd highest of 9, against a peer median of +31.5%.
  • Over three fiscal years its annual growth of +15.3% compares with a peer median of +39.9%.
CRDF Competitors Peer median
Weighted Avg Shares (Diluted) for CRDF and competitors
Company Period LTM YoY 3-year CAGR
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026100.04M +230.0%+40.6%
IPHAInnate Pharma S.A.FY202589.42M +10.3%+3.9%
FBRXForte Biosciences, Inc.LTM Mar 202688.77M +1552.7%+496.0%
MISTMilestone Pharmaceuticals Inc.LTM Mar 202686.73M +33.0%+25.5%
CRDFCardiff Oncology, Inc.LTM Mar 202667.15M +43.6%+15.3%
PEPGPepGen Inc.LTM Mar 202637.49M +15.0%+39.2%
MOLNMolecular Partners AGLTM Mar 202637.43M +9.0%+3.9%
ELTXElicio Therapeutics, Inc.LTM Mar 202616.57M +32.5%+70.3%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 202612.8M +30.5%+47.3%
Peer median (excluding CRDF) 62.11M+31.5%+39.9%

Competitors are the stored peer set for CRDF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue359K386K488K683K593K
Cost of Revenue00000
Gross Profit359K386K488K683K593K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development17.38M27.11M32.86M36.85M35.33M
Selling, General & Admin11.84M13.18M13.04M12.48M14.22M
Operating Expenses29.21M40.29M45.9M49.33M49.55M
Depreciation & Amortization451K236K398K404K904K
EBITDA(27.84M)(38.47M)(41.04M)(45.03M)(44.95M)
EBITDA Margin-7754.9%-9965.8%-8410.5%-6592.5%-7579.6%
Operating Income(28.86M)(39.9M)(45.41M)(48.65M)(48.96M)
Operating Margin-8037.6%-10337.3%-9305.7%-7123.1%-8256.3%
Interest Income264K1.58M4.07M3.26M3.1M
Interest Expense00000
Other Income / Expenses564K1.2M3.97M3.22M3.11M
Income Before Tax(28.29M)(38.7M)(41.44M)(45.43M)(45.85M)
Pre-Tax Margin-7880.5%-10026.9%-8492.0%-6651.7%-7732.0%
Income Tax Expense00000
Net Income(28.29M)(38.7M)(41.44M)(45.43M)(45.85M)
Net Margin-7880.5%-10026.9%-8492.0%-6651.7%-7732.0%
EPS (Basic)(0.73)(0.89)(0.93)(0.95)(0.69)
EPS (Diluted)(0.73)(0.89)(0.93)(0.95)(0.69)
Weighted Avg Shares39.03M43.6M44.68M47.65M66.84M
Weighted Avg Shares (Diluted)39.03M43.6M44.68M47.65M66.84M

Cardiff Oncology, Inc.

NASDAQ:CRDF

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.